drugset / Trial / NCT03802526

Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1805-R1 and NVP-1805-R2

NCT03802526

Phase 1 Completed 37 enrolled NVP Healthcare
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to compare the pharmacokinetics and safety/tolerability between NVP-1805-R1 and NVP-1805-R2

Timeline

Start
2019-04-03
Primary completion
2019-07-04
Completion
2019-09-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe Unknown 10 mg Oral
Subject Rosuvastatin Small molecule 20 mg Oral
Subject Telmisartan Other / unclassified 80 mg Oral

Indications

No indication recorded.